Capricor Therapeutics, Inc.
News
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
Globe Newswire SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...\n more…
Capricor Therapeutics Inc (NASDAQ:CAPR) Sees Significant Increase in Short Interest
Ticker Report Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of a large increase in short interest in August. As of August 15th, there was short interest totalling 7,000,000 shares, an...\n more…
Capricor Therapeutics (NASDAQ:CAPR) Share Price Passes Above 50-Day Moving Average of $4.43
Ticker Report Shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $4.43 and traded as...\n more…
HC Wainwright Comments on Capricor Therapeutics Inc's Q3 2024 Earnings (NASDAQ:CAPR)
Ticker Report Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Equities researchers at HC Wainwright dropped their Q3 2024 earnings estimates for Capricor Therapeutics in a note issued to investors on...\n more…
Capricor Therapeutics Second Quarter 2024 Earnings: Beats Expectations
Simply Wall St Capricor Therapeutics ( NASDAQ:CAPR ) Second Quarter 2024 Results Key Financial Results Revenue: US$3.97m (up 1.4% from...\n more…
Capricor Therapeutics (CAPR) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.29 per share a year ago. These...\n more…